Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

hOssicle

Financiado

Bioengineering of human ossicles as advanced in vivo hematopoietic model

hOssicle aims at developing miniaturized human bone organs in mice to be used as advanced model of healthy and malignant human hematopoiesis. In Europe, 80 million people are estimated to suffer from blood disorders. When at all... ver más

30/04/2026

LUNDS UNIVERSITET

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-10-27

ERC-2020-STG: ERC STARTING GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

LUNDS UNIVERSITET

1.50M€ | Lider

ESMALGLASS

109.80K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-40149-C02-01 ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANA... 70K€ Cerrado

SAF2016-75613-R ESPECIFICACION DE CELULA MADRE HEMATOPOYETICA Y LEUCEMICA 436K€ Cerrado

BES-2011-043382 BASES DE ENFERMEDADES CUTANEAS: DESARROLLO DE MODELOS EXPERI... 43K€ Cerrado

REBORN Full human based multi scale constructs with jammed regenera... 2M€ Cerrado

SAF2008-02099 CARACTERIZACION MOLECULAR Y CELULAR DE LAS POBLACIONES DE CE... 254K€ Cerrado

BFU2008-02010 FUNCION DE OSTERIX Y P38 EN OSTEOGENESIS INDUCIDA POR BMPS 169K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2020-10-27
Fecha Fin: 2026-04-30

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto hOssicle aims at developing miniaturized human bone organs in mice to be used as advanced model of healthy and malignant human hematopoiesis. In Europe, 80 million people are estimated to suffer from blood disorders. When at all existing, treatments are poorly effective: 92 % of new drugs successful in preclinical testing (animals and in vitro culture systems) fail in clinical trials. This urgently calls for the development of superior models, to refine our understanding of human hematopoiesis and better predict patient´ therapy efficacy. My laboratory has developed unique human mesenchymal lines capable of forming human ossicles by recapitulation of endochondral ossification -the developmental process of bone formation. These ossicles form subcutaneously in mice and display a similar structure and function to native mouse bones, but rely on human mesenchymal cells reconstituting a complex bone marrow environment specifically supporting the development of human hematopoiesis. hOssicle will offer the unprecedented custom engineering of human bones to understand the functional organization of its hematopoietic compartment. By genetic reprogramming of mesenchymal lines, I aim at controlling the molecular and cellular composition of the ossicles and study the corresponding impact on hematopoietic development. Finally, I envision the engineering of patient-specific ossicles with mesenchymal and leukemic blood cells from the same individual towards recapitulation of the disease setting. This will be a significant breakthrough, by offering the study of malignancy progression and drug-testing in a personalized in vivo context for cancer remission. By combining principles of bone development & tissue engineering, hOssicle proposes an organ engineering approach applied to hematopoiesis. The implications run from the identification of key factors controlling the production of blood cell types to the personalized modelling of leukemia and test of therapies.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores